Skip Navigation


JAC Advance Access originally published online on September 29, 2005
Journal of Antimicrobial Chemotherapy 2005 56(5):988-989; doi:10.1093/jac/dki357
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
56/5/988    most recent
dki357v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Freeman, J.
Right arrow Articles by Wilcox, M. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Freeman, J.
Right arrow Articles by Wilcox, M. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Correspondence

Surveillance for resistance to metronidazole and vancomycin in genotypically distinct and UK epidemic Clostridium difficile isolates in a large teaching hospital

Jane Freeman, Joanna Stott, Simon D. Baines, Warren N. Fawley and Mark H. Wilcox*

Department of Microbiology, University of Leeds and The General Infirmary, Leeds LS2 9JT, UK

* Corresponding author. Tel: +44-113-392-6818; Fax: +44-113-343-5649; E-mail: Mark.Wilcox@Leedsth.nhs.uk

Keywords: C. difficile , infections , treatment

The first 10% of the full text of this article appears below.

Sir,

Treatment of Clostridium difficile infection (CDI) has changed little since the recognition of the disease in the late 1970s. Currently accepted treatment options are essentially limited to oral metronidazole or vancomycin, ideally following withdrawal of the precipitating antimicrobial. Metronidazole is currently preferred due to its perceived clinical equivalence to vancomycin, in terms of overall response and rates of symptomatic recurrences, and lower cost.1 However, recent reports of poor clinical outcome following metronidazole therapy for CDI2,3 have prompted closer scrutiny of the treatment options and raised the issue . . . [Full Text of this Article]

Transparency declarations


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
S. D. Baines, R. O'Connor, J. Freeman, W. N. Fawley, C. Harmanus, P. Mastrantonio, E. J. Kuijper, and M. H. Wilcox
Emergence of reduced susceptibility to metronidazole in Clostridium difficile
J. Antimicrob. Chemother., November 1, 2008; 62(5): 1046 - 1052.
[Abstract] [Full Text] [PDF]